Volrustomig for high-risk locally advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 15 or older and weigh more than 35 kg (about 77 lbs).
- You have been diagnosed with locally advanced cervical cancer that has not spread to other parts of the body.
- You have not already had a hysterectomy or a fertility-sparing procedure planned.
- You must be able to provide a tumor sample for testing.
- You cannot have a history of autoimmune disease, organ transplant, or another cancer in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new immunotherapy drug, envafolimab, to standard chemotherapy and radiation can improve outcomes for patients with locally advanced cervical cancer. You may receive the experimental drug along with your usual treatment, which could help your body fight the cancer more effectively.
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
This trial tests a new drug called volrustomig, alone or with other cancer treatments, for people with advanced or metastatic solid tumors. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.